Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (RARE) Financial Statements


Ultragenyx Pharmaceutical Financial Overview

Ultragenyx Pharmaceutical's market cap is currently ―. The company's EPS TTM is $-8.025; its P/E ratio is -5.62; Ultragenyx Pharmaceutical is scheduled to report earnings on August 1, 2024, and the estimated EPS forecast is $-1.67. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 108.83M$ 127.39M$ 98.05M$ 46.33M$ 100.50M
Gross Profit$ 108.83M$ 127.39M$ 98.05M$ 108.31M$ 100.50M
EBIT$ -136.85M-$ -159.00M$ -159.10M$ -163.48M
EBITDA$ -131.76M--$ -156.95M$ -161.24M
Net Income Common Stockholders$ -170.68M$ -123.19M$ -120.01M$ -159.83M$ -163.97M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 412.08M$ 577.21M$ 442.09M$ 551.98M$ 629.35M
Total Assets$ 1.31B$ 1.49B$ 1.24B$ 1.31B$ 1.38B
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -412.08M$ -577.21M$ -442.09M$ -551.98M$ -629.35M
Total Liabilities$ 1.17B$ 1.22B$ 1.21B$ 1.18B$ 1.16B
Stockholders Equity$ 140.26M$ 275.41M$ 31.71M$ 129.03M$ 220.48M
Cash Flow-
Free Cash Flow$ -203.94M--$ -132.60M$ -181.90M
Operating Cash Flow$ -190.73M$ -83.90M$ -117.87M$ -116.16M$ -156.87M
Investing Cash Flow$ 94.44M$ -107.02M$ 64.30M$ 99.42M$ 111.30M
Financing Cash Flow$ -58.00K$ 330.61M$ 25.23M$ 33.01M$ -722.00K
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Ultragenyx Pharmaceutical Debt to Assets

Ultragenyx Pharmaceutical Cash Flow

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis